B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY

oleh: S. Zweegman, M. Agha, A.D. Cohen, Y.C. Cohen, S. Anguille, T. Kerre, W. Roeloffzen, D. Madduri, J.M. Schecter, K.C. De Braganca, C.C. Jackson, H. Varsos, P. Mistry, T. Roccia, X. Xu, K. Li, E. Zudaire, C. Corsale, M. Akram, D. Geng, L. Pacaud, P. Sonneveld, N. van de Donk